Gujarat Kidney IPO Day 1 LIVE: ₹251-crore Gujarat Kidney IPO opened for public subscription on December 22. The price band for the issue has been fixed at ₹108 to ₹114 per share. Gujarat Kidney IPO GMP today signals 6% listing pop.
Gujarat Kidney IPO Day 1 LIVE: Gujarat Kidney’s ₹251-crore initial public offering (IPO) has opened for bidding today, December 22, as the new week kicked off on Dalal Street. The mainboard offering will be available for bidding till December 24.
Gujarat Kidney IPO price band has been fixed at ₹108 to ₹114 per share.
The IPO consists entirely of a fresh issue of up to 2.2 crore equity shares, with no offer-for-sale (OFS) component. The company plans to use the funds for acquiring Parekhs Hospital in Ahmedabad, part-payment towards the acquisition of Ashwini Medical Centre, setting up a new hospital in Vadodara, and purchasing robotic equipment for the Vadodara facility. The funds will also be used for debt repayment, pursuing inorganic growth through potential acquisitions, and meeting general corporate expenses.
Ahead of the IPO launch, Gujarat Kidney raised slightly over ₹100 crore from anchor investors. According to a circular filed with the BSE on Friday, the anchor portion attracted investments from 10 entities, including Venus Investments, Khandelwal Finance Pvt Ltd, Nexus Global Opportunities Fund, and Sunrise Investment Opportunities Fund.
Gujarat Kidney IPO GMP
The grey market premium for Gujarat Kidney IPO remains decent. According to market sources, Gujarat Kidney IPO GMP today is ₹7. This means that shares of Gujarat Kidney are trading ₹7 above the offer price.
At the current GMP, Gujarat Kidney IPO listing price could be ₹121, a premium of 6% over the IPO price.
About Gujarat Kidney
Gujarat Kidney and Super Speciality is a regional healthcare provider based in central Gujarat, operating a network of mid-sized multi-speciality hospitals focused on secondary and tertiary care. The company currently runs seven hospitals with a combined bed capacity of 490.
For the financial year ended March 2025, the company reported revenue from operations of ₹40.24 crore and a net profit of ₹9.5 crore.
Track this space for LIVE updates on Gujarat Kidney IPO Day 1 details.
Gujarat Kidney IPO subscription status
By 2:54 PM on the first day of bidding, the public issue had been subscribed 0.94 times, the retail portion had been booked 3.83 times, whereas the NII segment had been filled 1.23 times.
Gujarat Kidney IPO comparison with listed peeers
As per the offer document, the company has shown Yatharth Hospital, GPT Healthcare, KMC Speciality Hospitals, as its listed peers. They are currently trading at a P/E of 44.0, 26.7, and 39.9 (as of December 16, 2025). However, they are not truly comparable on an apple-to-apple basis. This comparison appears to be an eyewash.
Gujarat Kidney dividend policy
The company has not declared any dividends for the referred periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.
Gujarat Kidney IPO details
The company operates through using leased property in Gujarat Multispecialty Hospital in Godhra and Gujarat Kidney and Superspeciality Hospital in Vadodara. In the past, it had acquired operational control in Raj Palmland Hospital Private Limited in Bharuch, M/s Surya Hospital and ICU in Borsad, Gujarat Surgical Hospital in Vadodara and Harmony Medicare Private Limited in Bharuch through acquisition of 51%, 90%, 90% and 51% holding respectively. Such acquisition of holding had allowed it to operate hospital without investing in land and building, medical equipment and necessary furniture and fixtures.
Gujarat Kidney IPO review
The company’s reputation, experienced management team, investment in medical technology, continual upgradation of its knowledge and sharing best practices has helped it to become a preferred choice for medical treatment, among masses. This has also helped it attract and retain talented healthcare professionals for its operations, which in turn draws more patients to its facilities and provides an added advantage.
Gujarat Kidney IPO subscription status
By 1:54 PM on the first day of bidding, the public issue had been subscribed 0.81 times, the retail portion had been booked 3.25 times, whereas the NII segment had been filled 1.06 times.
Gujarat Kidney IPO: Peers post-listing
Post-listing, Gujarat Kidney would be competing against its peers like Yatharth Hospital, GPT Healthcare, KMC Speciality Hospitals, etc.
Gujarat Kidney IPO review
As per the RHP, the company reported a net profit of ₹5.40 crore in the April–June quarter of FY26. For the full year, profit stood at ₹9.49 crore in FY25, compared with ₹1.71 crore in FY24. Revenue from operations came in at ₹15.26 crore in the April–June quarter of FY26. The company posted revenues of ₹40.24 crore in FY25, sharply higher than ₹4.77 crore in FY24.
Gujarat Kidney IPO subscription status
By 1:00 PM on the first day of bidding, the public issue had been subscribed 0.68 times, the retail portion had been booked 2.82 times, whereas the NII segment had been filled 0.84 times.
Gujarat Kidney IPO: Apply or not?
“The valuation looks aggressive at around 61x P/E, well above most listed hospital peers. The smaller scale also heightens risk, as execution delays or integration challenges could materially impact earnings,” Swastika Investmart report says.
Gujarat Kidney IPO review
It appears that post this issue, primary markets on the main board are likely to take a short holiday hopefully. It would be a good time to look at the over 103 issues listed in the year so far and final number of 105 that
Leave a Reply